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Abstract
Problem: The National Institute for Mental Health (NIMH) reports that only 1.2%
of adults suffer from OCD, but over 50% are severe (Obsessive Compulsive
Disorder (OCD), n.d.). Meier et al. (2016), found that patients with OCD faced a
40% higher chance of early mortality. Individuals with psychiatric conditions are
more at risk for poor physical health, poor education, economic struggles and
crime (Mental Health by the Numbers, 2019). Emergency departments claim
tens of millions of visits per year related to psychiatric issues resulting in billions
in costs each year (Mental Health by the Numbers, 2019). Genetic testing is
becoming a more frequently used tool in the battle against mental illness, but it
can be expensive and its value in improving clinical outcomes is still up for
debate (What is the cost of genetic testing, n.d.).
Methods: A descriptive, observational, quality improvement project aimed at
evaluating clinical outcomes among genetically tested patients with OCD.
Results: This quality improvement project included 15 patients (n=15), 6 who
were genetically tested (n=6, 40%) and 9 who were not (n=9, 60%). An analysis
of variance (ANOVA) was conducted based on an alpha value of 0.05 for each
clinical outcome and all were insignificant.
Implications for practice: Providers and Patients should seriously consider the
cost before utilizing routine genetic testing in patients with OCD. A larger
sample size should be used in future studies.
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Evaluating the Effects of Genetic Testing on
Patients with Obsessive Compulsive Disorder
Mental health conditions pose a serious burden in the US. The National
Alliance for Mental Health reports that 1 in 5 adults face mental health issues
each year (Mental Health by the Numbers, 2019). In 2017, that represented over
46 million individuals (Mental Illness, n.d.). When looking at obsessive
compulsive disorder (OCD) specifically, the National Institute for Mental Health
(NIMH) reports that while only 1.2% of adults suffer from OCD, over 50% of
those have impairment that is deemed “severe” (Obsessive Compulsive Disorder
(OCD), n.d.). A Danish study in 2016 by Meier et al., found that even after
accounting for associated disorders and substance abuse, patients with OCD
faced a 40% higher chance of early mortality compared to the general
population. Genetic testing is becoming a more frequently used tool in the battle
against mental illness, but it can cost anywhere between $100-$2000 and its
value in improving clinical outcomes is still up for debate (What is the cost of
genetic testing, n.d.). This project will seek to answer the study question: What
effect does genetic testing have on clinical outcomes such as medication
changes, side effects, tolerance and therapeutic response in patients aged 18-60
being treated for OCD compared to those who only undergo traditional clinical
assessment and management?
According to the NIMH, OCD affects women more than men and young
adults show the highest incidence (Obsessive Compulsive Disorder (OCD), n.d.).
The second leading cause of death in individuals ages 10 to 34 is suicide (Mental
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Health by the Numbers, 2019). Individuals who struggle with psychiatric
conditions are more at risk for deterioration of physical health as well as issues
with poor education, economic struggles and crime (Mental Health by the
Numbers, 2019). Emergency departments claim 10’s of millions of visits per year
related to psychiatric issues resulting in billions of dollars in treatment costs each
year (Mental Health by the Numbers, 2019).
Treating mental health diagnoses is complex with unique challenges.
Treatment is often an emotional roller-coaster as the hope of a new drug is often
followed by disappointment when, after weeks of waiting, it proves ineffective or
intolerable. This cycle can be repetitive resulting in despair, hopelessness and
ultimately defeat leading patients to cease treatment rather than face another
painful cycle. In addition, potentially life altering side effects may occur with many
mental health medications leading patients to struggle with treatment adherence.
Genetic testing may offer a potential “short cut” by identifying a patient’s
specific genetic variations allowing the provider to select the most effective and
least disruptive medication for that specific patient much sooner, reducing
treatment failure and non-adherence. For example, Smits et al. (2007) showed
that among patients with depression, up to 40% will be resistant to SSRI’s, the
current first line treatment, due to genetic variations related to Serotonin
processing. Using that information in treatment selection for patients with major
depression increased the 6-week remission rate by almost 5% (Smits et al.,
2007).
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Current practices at a psychiatric outpatient clinic in a large mid-western
city vary widely from provider to provider. The clinic has been utilizing the
Genomind test for approximately two years. Some providers are highly motivated
to use the test to guide their treatment plan, while others are unsure of the value
of testing and prefer to rely on traditional clinical assessment alone. Some tests
are reserved for highly treatment resistant patients, while others are targeted
towards specific diagnoses. Patient input is often a determining factor as some
patients are resistant to offering up their DNA while others simply “want to know”.
For some patients, finding that their genetics explain why they are struggling is
confirming and helpful in coming to terms with their condition. The findings of this
quality improvement project may help to guide future practice.
Review of Literature
This project began with a review of the current literature as it pertained to
the topic of the effectiveness of genetic testing in mental health, anxiety and
OCD. The databases of PubMed, CINAHL and Google Scholar were searched
for articles using various combinations of the terms mental health, behavioral
health, psych*, effectiveness, anxiety, OCD, clinical outcomes, side effects,
therapeutic response, medication changes, genetic and genomic testing. Articles
were limited to having been published between January 1st, 2015 and the
present.
Three articles discussed the basics of genetic testing and its role in
anxiety disorders. McGowan (2019) explains the current status of studies relating
to anxiety and genetic testing and provides evidence that multiple gene variants
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could account for variations of severity of disease as well as response to
medications. Tomasi et al. (2019) also discussed current knowledge of specific
genetic variants as they pertained to anxiety disorders. Both articles emphasize
the serotonin system. Smoller (2015) elaborates on what is and isn’t known
regarding the role of genetic variants in these disorders. All three articles discuss
the complexity of the anxiety family of disorders and inconsistencies among
current knowledge and acknowledge that while there are known genetic markers
of interest, there is much room for further study specific to anxiety disorders.
One study, by Perlis et al., (2018), focused on cost effectiveness of
genetic testing for anxiety patients, as the test can be as high as $2000 (What is
the cost of genetic testing, n.d.). After comparing health claims between anxiety
patients who received genetic testing to those who had not, it was determined
that the tested group had statistically significant reductions in emergency room
visits and hospitalizations resulting in an estimated savings of almost $2,000 over
the 6 months (Perlis et. al, 2018). This potential savings could help justify the
cost.
Three articles focused on the overall utility of genetic testing in anxiety
disorder patients. A 2017 article by Tiwari et al. analyzed the Individualized
Medicine: Pharmacogenetic Assessment and Clinical Treatment (IMPACT) study
and the MEDCO dataset to evaluate the effectiveness of genetic testing. It was
determined that there were statistically significant reductions of symptoms and
benzodiazepine usage post genetic testing. Bradley et al., (2017) found
statistically significant improvement in outcomes among patients with depression

Running Head: EFFECTS OF GENETIC TESTING

7

and anxiety whose treatment was based on genetic testing when compared to
the untested groups. The 2018 systematic review by Solomon, Cates and Li
(2019) examined 16 studies between 2013 and 2018. While data was
inconsistent, it was inferred that testing may benefit the population even though it
may not necessarily equate to improved outcomes. Further research was
recommended to determine whether the use of genetic testing translates to
actual improvement in clinical outcomes.
A deeper review of the literature specifically regarding genetic testing as it
pertains to OCD revealed 4 additional articles. Song et al. (2017) found that
mutations within the SLITRK5 gene were implicated in OCD in both mice and
humans. Other articles spoke to the role of neurotransmitters and their
involvement in patient response to selective serotonin reuptake inhibitors
(SSRIs). Sina, Ahmadiani, Asagi and Shams (2018) found a link between HTR2A
haplotypes and therapeutic response to fluvoxamine in patients with OCD.
Contrarily, Gomes et al. (2018) was unable to find a correlation with OCD and
HTR2A but did find strong associations with OCD and the polymorphism in
SLC6A4 STin2, another gene involved in serotonin transportation. Umehara et al.
(2016) identified the calcium signaling pathway as being associated with
therapeutic response to both SSRIs and SSRIs combined with antipsychotics.
In summary, genetic markers and variants among individuals can play a
role in the presentation of anxiety and OCD as well as the response to
medication therapy. Evidence has shown various benefits of genetic testing in
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reducing medication costs and usage. There is insufficient data regarding
improvement in clinical outcomes among genetically tested patients.
Method
Design
This project was a descriptive, observational, quality improvement project
aimed at evaluating the clinical outcomes of prescribed medication changes, side
effects, medication tolerance and therapeutic response among genetically tested
patients with OCD compared to OCD patients who are not tested.
Framework
This project followed a Plan-Do-Study-Act (PDSA) framework. Each step
is discussed further in the subsequent sections. This project evaluated the effects
of genetic testing on clinical outcomes among patients with OCD. To execute this
the researcher compared a convenience sample of OCD patients whose
treatment was based on genetic testing to a convenience sample of OCD
patients whose treatment was based only on traditional clinical diagnosis and
assessment. A retrospective chart review of a 6-month period was used to
evaluate each group and the effects of genetic testing on the clinical outcomes of
medication changes, side effects, tolerance of medications and therapeutic
response compared between the two groups.
Setting
This project took place in an outpatient psychiatric care clinic in a large
mid-western city. The practice employs one physician and four nurse
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practitioners and treats both pediatric and adult patients with all types of mental
health conditions, including substance abuse.
Sample
In addition to obtaining the necessary approvals, the planning of the
sample process was included in the Plan portion of the PDSA. The sample was a
convenience sample of patients meeting the inclusion/exclusion criteria.
Included for study were patients aged 18-60, seeking treatment for OCD whose
initial visit and/or initial genetic test fell within the 12-month window between
January 1st and December 31st of 2019. Excluded from the study were any
patients exhibiting suicidal thoughts or intent, those with concurrent diagnoses of
any personality disorders, those who were not actively being treated for OCD or
related complications, and any patients who did not continue care for at least 6
months following initiation of treatment. These were divided into two groups:
patients who received genetic testing within that time frame and patients who did
not.
Data Collection
Data collection made up the Do section of the PDSA framework. Following
clinic and IRB approval, read-only access to the medical records was obtained
from the clinic. Data was collected via retrospective chart review. Data collected
included patient demographics divided categorically to protect patient identities,
initial anxiety scores based on the Patient Health Questionnaire (PHQ-9) and
initial treatment recommendations among both groups. Data collected at three
and six months included genetic markers/variants found, subsequent PHQ-9
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scores, level of therapeutic response to initial recommended therapy (ie. no
response, sub-therapeutic, therapeutic), side effects experienced (divided by
category type), whether or not the side effects were tolerable, and number of
medication changes. All data was collected and organized using a Word
document collection tool (Appendix A) and then entered into Intellectus Statistics
for analysis. All data was de-identified, coded and protected for patient privacy.
Names were removed, and ages were coded by broad categories rather than
actual age (ie. 18-24, 25-34, etc.). While genetic markers and variants found via
testing were listed, these are found in all humans, making it impossible to utilize
this data to track back to any single individual. All paper collection tools were
stored in a locked filing cabinet and all records were accessed via a single,
password protected laptop, both accessible to the researcher alone. Data will be
secured in the same manner for 5 years, after-which it will be deleted or
shredded utilizing the clinic’s professional shredding service.
Data Analysis
Data Analysis made up the Study portion of PDSA. Data was analyzed
using Intellectus Statistics. Descriptive data such as mean age group, gender,
etc., was extrapolated on both groups to summarize the samples. ANOVA was
utilized to compare the control group of patients receiving traditional clinical
assessment-based care to OCD patients who received care guided by genetic
testing to evaluate whether or not the genetic group showed significant changes
in the identified clinical outcomes. These changes may have included greater
reduction of PHQ9 scores, higher level or sooner reaching of therapeutic
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response, less or more tolerable side effects, or less changes to medications.
The Act portion of PDSA included any recommendations to the clinic in terms of
how they utilize genetic testing which can be made based on the findings of this
project.
Approval Process
An integral part of the Plan of PDSA, organizational approval was
obtained after an in-person verbal proposal presentation given to all providers
and clinic staff at the clinic’s weekly provider meeting. Committee approval
through UMSL was obtained after project proposal defense. UMSL IRB approval
was received.
Results
A retrospective chart review of the clinic’s patients who met criteria
resulted in a total of 15 patients (n=15), 6 who were genetically tested (n=6, 40%)
and 9 who were not (n=9, 60%). 100% (n=15) of the patients selected were
female. The most frequently observed categories of age were 18-24 and 25-34,
each with an observed frequency of 5 (33%).
GRIK1 is the glutamate receptor and is highly associated with anxiety
disorders such as OCD (Terbeck, Akkus, Chesterman, & Hasler, 2015.). It can
present as A/A, A/C, or C/C and the C allele is associated with alcohol addiction.
C allele carriers have shown good response to Topiramate when compared with
Placebo (Selfdecode, n.d.). When examining the genetic variants among the
tested patients, the most frequently observed category of Grik1 was A/C (n = 3,
50%).
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ANK3 is involved in the production of homocysteine and variations of this
gene may be associated with methylenetetrahydrofolate reductase deficiency. It
can present as C/C, C/T, or T/T and the presence of the T allele is associated
with bipolar disorder and attention deficits (Genecards, n.d.). The most frequently
observed category of ANK3 was C/C, or normal (n = 6, 100%).
CACNA1c is a gene involved in producing calcium channels and may be
associating with learning and rewards processing and can present as A/A, A/G or
G/G and the presence of an A allele is associated with bipolar disorder
(Genecards, n.d). The most frequently observed category of CACNA1c was G/G
(n = 5, 83.3%).
SL64A is a sodium-dependant transporter gene involved in the movement
of serotonin between synapses (PubChem, n.d.). It has multiple alleles and can
present as La/La, Lg/Lg, L/S, or S/S with the S allele being highly associated with
depression. The most frequently observed category of SL64A was L/S (n = 4,
66.67%).
COMT is an enzyme that helps break down neurotransmitters in the prefrontal cortex such as epinephrine and dopamine (Selfdecode, n.d.). It may
present as Val/Val, which have high levels of COMT activity resulting in lower
dopamine levels, Met/Val or Met/Met which has the lowest levels of activity and
therefor higher levels of dopamine (GeneCards, n.d.). The most frequently
observed category of COMT was Met/Val, or normal (n = 4, 66.67%).
Frequencies and percentages are presented in Table 1.
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An analysis of variance (ANOVA) was conducted based on an alpha value
of 0.05 for each clinical outcome to determine whether there were significant
differences between the genetically tested group and the non-tested group.
For medication changes at 3 months, the results of the ANOVA were not
significant, F(1, 13) = 1.62, p = .226. For number of medication changes at 6
months, the results of the ANOVA were not significant, F(1, 13) = 0.01, p
= .909. ). The means and standard deviations are presented in Table 2 and Table
3, and can be visualized in Figure 1.
For medication tolerance at 3 months, the results of the ANOVA were not
significant, F(1, 13) = 0.00, p = 1.000. For therapeutic response at 3 months, the
results of the ANOVA were not significant, F(1, 13) = 1.56, p = .234. For side
effects at 3 months, the results of the ANOVA were not significant, F(1, 13) =
0.24, p = .635. These findings indicated there were no significant differences in
clinical outcomes at 3 months between the genetically tested group and the nontested group (Table 2). The percentages and standard deviations are presented
in Table 2.
For medication tolerance at 6 months, the results of the ANOVA were not
significant, F(1, 13) = 1.56, p = .234. For therapeutic response at 6 months, the
results of the ANOVA were not significant, F(1, 13) = 0.04, p = .847. For side
effects at 6 months, the results of the ANOVA were not significant, F(1, 13) =
0.01, p = .939. These findings indicated there were no significant differences in
clinical outcomes at 6 months between the genetically tested group and the non-
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tested (Table 3). The percentages and standard deviations are presented in
Table 3 and can be visualized in Figure 2.
An analysis of variance (ANOVA) was also conducted to determine
whether there were significant differences in PHQ9 scores over time by genetic
testing.
The ANOVA was examined based on an alpha value of 0.05. The results
of the ANOVA were not significant, F(1, 13) = 0.13, p = .720, indicating the
differences in change for the PHQ9 scores from initial to 6 months between the
genetically tested group and the non-tested group were similar and not significant
(Table 4). The means and standard deviations are presented in Table 5.
Discussion
Genetic testing is becoming increasingly available to providers and
patients to aid in guiding treatment for mental health conditions. While the
literature suggests that genetic testing may offer many insights into the
functioning of various systems as they relate to mental health disorders, this
quality improvement project aimed to see if testing translated to improved clinical
outcomes. No significant differences in clinical outcomes were found among the
genetically tested group compared to the group that was treated with traditional
diagnosis and management. Of note, all variables showed considerably better
outcomes at the 6 months compared to at 3 months, regardless of testing group
suggesting that effective treatment of mental health takes time, persistence, and
patience.
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Upon reflection, several factors may have contributed to the lack of
statistical significance. Despite reviewing one year of patients seen, the sample
size was very small. This was due to the researcher’s efforts to find the most
accurate, homogenous sample. The study did not account for practice
differences among the five providers and differences in how they utilize the
genetic findings in their treatment plans. Finally, the PHQ9 screening tool, while
helpful in gauging generalized data on patient progress with depression, may not
have been the most accurate tool in reflecting progress with OCD symptoms.
Conclusion
This quality improvement project did not find evidence to suggest that
clinical outcomes are improved after genetic testing. Recommendations for future
practice would include discouraging routine genetic testing for OCD patients as
traditional diagnosis and management showed similar clinical outcomes
compared to the genetically tested group in this project. Any discussion regarding
genetic testing should be done thoughtfully between patient and provider when
considering treatment options. Given the potentially high cost of genetic testing to
patients and the healthcare system as a whole, providers should take great care
before choosing to utilize genetic testing in this patient population. Future studies
evaluating clinical outcomes as they relate to genetic testing in patients with OCD
should consider utilizing a larger sample size, controlling for practice methods by
focusing on a single provider and utilizing a screening tool specific for OCD.
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Table 1.
Frequency Table for Nominal Variables
Variable
Age
18-24
25-34
35-44
45-54
55-60
Sex
female
Genetic Testing
yes
no
Grik1
C/A
C/C
A/A
ANK3
C/C
CACNA1c
A/A
G/G
SL64A
La/La
L/S
COMT
Met/Met
Met/Val

n

%

5
5
3
1
1

33.33
33.33
20.00
6.67
6.67

15

100.00

6
9

40.00
60.00

3
2
1

50.00
33.33
16.67

6

100.00

1
5

16.67
83.33

2
4

33.33
66.67

2
4

33.33
66.67

Note. Due to rounding errors, percentages may not equal 100%.
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Table 2.
ANOVA for 3 months
Variable
Number of Med
Changes
Tolerability
yes
no

Genetically tested

F

p

1.62

0.226

0

1

%

Not tested

M

SD

n

1.83

1.94

6

0.52

6

33.33
66.67

Therapeutic Response
none
sub
therapeutic

1.56

Side Effects
none
sleep
weight
mood
headaches
GI

0.24

0.234

6

0
66.67
33.33

SD

n

3.44

2.65

9

0.5

9

0.5

9

1.32

9

11.11
77.78
0

1.26
66.67
16.67
16.67
0
0
0

M

66.67
33.33
0.52

0.635

%

6
77.78
11.11
0
0
11.11
0
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Table 3.
ANOVA for 6 Months
Variable
Number of Med
Changes

F

Genetically Tested
p

%

0.01 .909

Tolerability
yes
no

1.56

Therapeutic Response
none
sub
therapeutic

0.04

Side Effects
none
sleep
weight
mood
headaches
GI

0.01

Not Tested

M

SD

n

1.67

2.25

6

.41

6

.234
83.33
16.67
.847

0.52

6

0
50.00
50.00

SD

n

1.78

1.48

9

0.00

9

.53

9

1.67

9

0
44.44
55.56
.55

50.00
50.00
0
0
0
0

M

100.00
0
.55

.939

%

6
88.89
0
0
0
0
11.11
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Table 4.
Analysis of Variance Table for change over time for PHQ9 from initial to 6
months by genetic testing
Term
Genetic testing
Residuals

SS
7.51
726.22

df
1
13

F
0.13

p
.720

ηp2
0.01

Running Head: EFFECTS OF GENETIC TESTING
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Table 5.
Mean, Standard Deviation, and Sample Size for change over time by genetic
testing
Combination
Yes
No

M
-8.33
-6.89

SD
9.22
6.13

n
6
9

Running Head: EFFECTS OF GENETIC TESTING
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Figure 1.

Medication changes at 3 and 6 months
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Figure 2.

Clinical Outcomes at 3 and 6 Months
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